Evidence map›Paper›PMID 36131010›Full record

ArticleProstate cancer and prostatic diseases2024

Allopurinol and prostate cancer survival in a Finnish population-based cohort.

Ville Kukko, Antti Kaipia, Kirsi Talala, Kimmo Taari, Teuvo L J Tammela, Anssi Auvinen, Teemu J Murtola

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ville KukkoFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. ville.kukko@tuni.fi.ORCID 0000-0001-9584-8693
Antti KaipiaDepartment of Urology, Tampere University Hospital, Tampere, Finland.
Kirsi TalalaFinnish Cancer Registry, Helsinki, Finland.
Kimmo TaariDepartment of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Teuvo L J TammelaFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Anssi AuvinenFaculty of Social Sciences, University of Tampere, Tampere, Finland.
Teemu J MurtolaFaculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Tampere University · FIFinnish Cancer Registry · FITampere University Hospital · FIUniversity of Helsinki · FI

Funding

Academy of Finland (Suomen Akatemia) 312330724Pirkanmaan Sairaanhoitopiiri (Pirkanmaa Hospital District) 9AC059
6 · The paper itself

Abstract

backgroundAllopurinol is gout medication that inhibits uric acid formation. Its possible anti-carcinogenic properties have been under research in past years. Studies based on Taiwanese registries showed that long term allopurinol use might reduce prostate cancer (PCa) incidence. However, our studies based on Finnish registries did not support those findings. In this study, we evaluate whether allopurinol use is associated with prostate cancer-specific survival (CSS) or overall survival (OS) in a Finnish population-based cohort.

methodsThe study cohort was originally enrolled for the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). We included all newly diagnosed PCa cases during 1996-2015, 9252 men in total. Information on allopurinol purchases was from the national prescription registry of the Social Insurance Institution of Finland. Information about deaths, treatments, and use of other medications was obtained from registries, and tumor stage and PSA at diagnosis from medical records. Follow-up started at diagnosis, and we analysed separately two endpoints: PCa-specific death and overall death. We used an extended Cox regression with adjustment for age at diagnosis, Charlson comorbidity index, FinRSPC trial arm, use of other drugs and EAU PCa risk group.

resultsDuring a median follow-up of 9.86 years, 2942 deaths occurred, including 883 from PCa. There was no difference in CSS between allopurinol user and non-users, but allopurinol users had lower OS (multivariable-adjusted hazard ratio 1.77; 95% CI: 1.57-2.00). However, this decrease in OS was mitigated along with increasing intensity of allopurinol use.

conclusionsWe found no marked difference in CSS by allopurinol use. Allopurinol users had lower OS but there were no significant differences by duration or intensity of allopurinol use. Allopurinol use may not have anticancer effects against prostate cancer; instead, it may be a surrogate for metabolic problems causing shorter OS among men with PCa.

Indexed as

Prostatic NeoplasmsAllopurinolFinlandHumansMaleProstateRisk FactorsAllopurinol

Identifiers

PMID36131010
PMCPMC10876474
OpenAlexW4297879060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.